Готові списки джерел за темами / 321.804 3

Зміст

  1. Статті в журналах
  2. Книги
  3. Частини книг
  4. Тези доповідей конференцій
  5. Звіти організацій

Добірка наукової літератури з теми "321.804 3"

Автор: Grafiati
Опубліковано: 19 липня 2022

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "321.804 3".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "321.804 3"

1

le Coutre, Philipp D., Francis J. Giles, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Andreas Hochhaus, et al. "Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study,." Blood 118, no. 21 (November 18, 2011): 3770. http://dx.doi.org/10.1182/blood.v118.21.3770.3770.

Повний текст джерела
Анотація:
Abstract Abstract 3770 Background: Nilotinib is a selective and potent BCR-ABL TKI approved for the treatment of pts with newly diagnosed Ph+ CML-CP, and for pts with CML-CP or CML-AP resistant to or intolerant of imatinib. Here, we present the 48-mo follow-up data from the 2101 trial for pts with imatinib resistance or intolerance. Methods: Pts were treated with nilotinib 400 mg twice daily (BID). Key endpoints included PFS (defined as progression to AP/BC or discontinuation due to disease progression as assessed by investigator or death from any cause) and OS (includes deaths during treatment or follow-up after discontinuation). Results: 321 pts were enrolled (70% imatinib resistant; 30% imatinib intolerant with resistance). At baseline (BL), 36% of pts were in CHR. At the time of data cutoff, 224/321 pts (70%) discontinued nilotinib therapy (Table), and 31% of all pts had at least 48 mo of treatment. The median nilotinib dose intensity was 789 mg/day (range, 151–1110) and 62% of pts received ≥ 400 mg BID nilotinib as their last dose available. Pts with BL CHR had a significantly higher PFS rate at 48 mo vs pts without BL CHR (71% vs 49%, respectively; P =.001). Only 11 (3%) pts progressed to advanced disease (AP/BC) during study. Estimated 48-mo OS rate was 78% (95% CI 74%-83%). Among resistant pts, those without BL mutations (n = 92) had a significantly higher OS rate at 48 mo vs pts with sensitive mutations at BL (n = 78) (84% vs 74%, respectively, P =.029); however, there was no significant difference in OS among pts with sensitive and insensitive mutations (Y253H, E255K/V or F359C/V, n = 27) at BL (74% vs 71%, respectively, P =.804). No new safety signals were observed, and few additional AEs were reported since 24 mo follow-up (Table). Biochemical lab abnormalities were generally mild, transient, and easily managed; grade 3/4 lipase elevation (19%), hypophosphatemia (18%), and hyperglycemia (13%) were most common. Reports of any-grade pleural effusions remained low (1%), and no new cases were reported with longer follow-up. No new cases of QTcF >500 ms and 3 new cases of QTcF increases > 60 ms from BL were reported. Nine pts died during treatment or within 28 days of discontinuation: 8 deaths were previously reported and occurred in the first 24 mo of follow-up; 1 additional death due to lung neoplasm occurred between 24 and 48 mo (35 mo). Conclusions: With longer follow up, nilotinib continues to be effective and well tolerated in pts with Ph+ CML-CP resistant to or intolerant of imatinib therapy. Nilotinib prevented progression to AP/BC in the majority of pts on treatment and was associated with high OS rates. No cumulative toxicity was observed. Data demonstrating the higher rate of PFS in pts who entered the study with a BL CHR suggest that switching pts to nilotinib prior to hematologic failure on imatinib, and according to current treatment guidelines, may maximize the efficacy of nilotinib therapy. Disclosures: le Coutre: Novartis: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria. Giles:Novartis: Consultancy, Honoraria, Research Funding. Pinilla-Ibarz:Novartis: Research Funding, Speakers Bureau. Larson:Novartis: Consultancy, Honoraria, Research Funding. Gattermann:Novartis: Honoraria, Research Funding. Ottmann:Novartis: Consultancy; BMS: Consultancy, Research Funding. Hochhaus:Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Ariad: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria, Research Funding. Radich:BMS: Consultancy; Novartis: Consultancy, Research Funding. Saglio:Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Pfizer: Consultancy. Hughes:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees. Martinelli:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Pfizer: Consultancy. Kim:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding. Branford:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Research Funding; Ariad: Research Funding. Müller:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Shou:Novartis: Employment. Novick:Novartis: Employment, Equity Ownership. Fan:Novartis: Employment. Cortes:Novartis: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Ariad: Consultancy, Research Funding. Baccarani:Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau. Kantarjian:Novartis: Consultancy, Research Funding; BMS: Research Funding; Pfizer: Research Funding.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Mounce, Luke TA, Willie Hamilton, and Sarah ER Bailey. "Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care." British Journal of General Practice 70, no. 698 (July 27, 2020): e622-e628. http://dx.doi.org/10.3399/bjgp20x710957.

Повний текст джерела
Анотація:
BackgroundA raised platelet count (thrombocytosis) measuring >400 × 109/l is associated with high cancer incidence. It is uncertain whether platelet counts at the upper end of the normal range (high-normal: 326–400 × 109/l) are also associated with cancer.AimTo investigate cancer incidence following a normal platelet count in primary care.Design and settingA prospective cohort study was undertaken using data from the Clinical Practice Research Datalink and National Cancer Registration and Analysis Service, dating from 1 May 2005 to 30 April 2014.MethodOne-year cancer incidence was estimated for 295 312 patients with normal platelet counts (150–400 × 109/l). Patients with platelet counts >325 × 109/l were oversampled to maximise precision of estimates of cancer incidence. All patients were aged ≥40 years with no prior cancer diagnoses. The effects of age, sex, and smoking were explored. Non-melanoma skin cancers were omitted from exclusions and incidence.ResultsOne-year cancer incidence increased greatly with age, male sex, and higher platelet count. Males aged ≥60 years with a high-normal count had an incidence of 4.2% (95% confidence interval [CI] = 4.0 to 4.4). The highest incidence of 6.7% (95% CI = 5.3 to 8.4) was found in males aged ≥80 years, who had platelets in the range of 376–400 × 109/l; this was 3.1 percentage points higher than the incidence for patients in the same age group with lower-normal counts of 150–325 × 109/l. Risks for all female subgroups were <3%. Patients with high-normal platelet counts were most at risk of lung and colorectal cancers and, in general, had advanced-stage cancer at diagnosis.ConclusionPlatelet counts at the high-normal range in males aged ≥60 years may be indicative of an underlying malignancy, and referral for further investigation should be considered.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Ollivierz, L. "Genetic differences in recombination frequency in the pig (Sus scrofa)." Genome 38, no. 5 (October 1, 1995): 1048–51. http://dx.doi.org/10.1139/g95-139.

Повний текст джерела
Анотація:
A comparison has been performed on 3 recently published linkage maps of the pig, hereafter designated as the American (A), European (E), and Swedish (S) maps. The cumulated distances between common markers in these 3 maps were in the ratio 1.00 (A): 0.88 (E): 0.77 (S), in keeping with the ratio of the percentages of domestic genome in the reference families used to build the corresponding maps, i.e., 1.00 (A): 0.81 (E): 0.50 (S). From further recombination frequencies reported in wild boars (in the S report), the wild pig genome length (in centimorgans) is expected to represent 66% of the domestic pig genome length. These observations tend to confirm a general result of Burt and Bell (Nature (London), 326: 803–805 (1987)), showing higher chiasma frequencies in domestic mammalian species compared with wild species. Consequences for mapping studies are discussed.Key words: recombination, pig, microsatellites, chiasmata.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cada, Dennis J., Terri L. Levien, and Danial E. Baker. "Perampanel." Hospital Pharmacy 48, no. 4 (April 2013): 321–31. http://dx.doi.org/10.1310/hpj4804-321.

Повний текст джерела
Анотація:
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2013 monograph topics are alogliptin, crofelemer, lomitapide, ponatinib, and sumatriptan iontophoretic transdermal. The DUE/MUE is on alogliptin.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Liu, S., M. C. Ha-Thi, and R. Schläfer. "311 Lysyl Oxidase Antagonizes RAS Oncogene-mediated Transformation." European Journal of Cancer 48 (July 2012): S76. http://dx.doi.org/10.1016/s0959-8049(12)71004-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Cain, Joe. ": Aydon, C.Charles Darwin. Robinson, London: 2003. Pp xxvi, 326. Price £ 7.99. ISBN 1-84119-801-3 (paperback)." Archives of Natural History 31, no. 2 (April 2005): 369–70. http://dx.doi.org/10.3366/anh.2005.31.2.369.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Chadwick, Owen. "Theologische Realenzyklopädie, xiv. Gottesdienst–Heimat. Edited by Gerhard Müller. Pp. 804 + 39 ills, and 3 maps. Berlin–New York: Walter de Gruyter, 1985. DM 320. 3 11 008583 6." Journal of Ecclesiastical History 37, no. 4 (October 1986): 664–65. http://dx.doi.org/10.1017/s0022046900022442.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Abou-Alfa, G. K., J. A. O'Donoghue, B. Gansukh, J. Ma, S. Ruan, M. Koga, R. Lee, N. Ohishi, T. Othomo, and J. A. Carrasquillo. "328 124I GC33 Positron Emission Tomography (PET), Imaging Biomarker of Glypican-3 in Hepatocellular Carcinoma." European Journal of Cancer 48 (November 2012): 100. http://dx.doi.org/10.1016/s0959-8049(12)72126-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

ZHANG, JIANJUN, and JUNHONG DUAN. "SYNTHESIS AND CHARACTERIZATION OF SPHERE-LIKE ZnS NANOCRYSTALS BY THERMOLYSIS OF A NEW COMPLEX PRECURSOR." Modern Physics Letters B 24, no. 19 (July 30, 2010): 2091–99. http://dx.doi.org/10.1142/s0217984910024456.

Повний текст джерела
Анотація:
In this paper, the preparation and optical properties of sphere-like ZnS nanocrystals are reported. Pure and uniform cubic-phase sphere-like ZnS nanocrystals with grain sizes of 30–40 nm were synthesized by thermolysis of a new precursor complex ( enH 2)0.5[ Zn ( en )3]( SCN )3 (en = ethylenediamine) in nitrogen stream at 800°C. The as-synthesized products were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS) and X-ray photoelectron spectroscopy (XPS), respectively. The XRD analysis reveals the phase of ZnS with cubic zinc blende. UV-Vis and photoluminescence spectra (PL) were utilized to investigate the optical properties of sphere-like ZnS nanocrystals. By testing on UV-Vis spectra, it is concluded that the limiting wavelength of the ZnS nanocrystals is 320 nm and the band gap is 3.88 eV. In room temperature PL spectra, one strong emission peak centered at 322 nm is discovered, which could be attributed to the band to band transitions. The above-mentioned results showed that the thermolysis method is preferable for synthesizing high-quality sphere-like ZnS nanocrystals. The synthesized precursor could be used as morphological templates to prepare nanostructure inorganic compounds.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Yasuda, Y., H. Furusawa, Y. Maeda, and K. Komaki. "327 The Serum HER-2 Reflects the Tumor Burden of Breast Cancer." European Journal of Cancer 48 (March 2012): S138. http://dx.doi.org/10.1016/s0959-8049(12)70393-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "321.804 3"

1

Munoz, Antonio Molina. El invierno en Lisboa. Madrid: Seix Barral, 1995.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Prieto, A. La enfermedad del amor. Barcelona: Seix Barral, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Los eucaliptos. Muchnik, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Hidden Agendas: Unreported Poetics. Litteraria Pragensia, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Móviles de animales. Barcelona: Ceac, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Los eucaliptos. Muchnik, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

La estrella que cayo del cielo. Artime, 2005.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

La conexión Alejandría. Barcelona: Seix Barral, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Totalidad sexual del cosmos. Seix Barral, 2019.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

La conexión Alejandría. Barcelona: Seix Barral, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "321.804 3"

1

Kumar, M. "804 Chemical Shifts and Coupling Constants for C8H16NO3PS." In Chemical Shifts and Coupling Constants for Phosphorus-31, 813. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_806.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lukurugu, Gerald Alex, Omari Kalanje Mponda, Essegbemon Akpo, Emmanuel S. Monyo, Joseph Nzunda, Happy Daudi, Athanas Joseph, Hamphfrey George Mlimbila, David Ndolelwa, and Charles Mkandawile. "Groundnut Seed Production and Distribution Through Multi-Stakeholder Platforms in Southern Region of Tanzania." In Enhancing Smallholder Farmers' Access to Seed of Improved Legume Varieties Through Multi-stakeholder Platforms, 9–30. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8014-7_2.

Повний текст джерела
Анотація:
AbstractSouthern Groundnut Platform (SGP) was established in 2016 to enhance seed access and adoption of improved groundnut varieties by farmers. The platform serves all districts in Lindi and Mtwara regions and Tunduru district in Ruvuma region. The platform has 53 members of which 22 are females and 31 are males. Since its establishment, there has been a marked increase in farm advisory services using government extension officers, community extension services and lead farmers. Groundnut seed production and distribution networks have increased to include more actors such as NGOs, seed companies, farmers groups and individual seed entrepreneurs. The increased seed access to farmers in the southern zone has contributed to 11% increase in area under cultivation resulting in 15% increase in groundnut production in Nanyumbu district between 2012 and 2018. New market linkages formed helped improve farm gate prices by 80% (from Tshs. 1000 to 1800). The platform also introduced 29 new labour saving technologies reducing women drudgery and increasing farmer improved varieties choice from 3 to 11 new varieties released between 2009 and 2018.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Duncan, Ray. "Int 15H Funktion 80H Gerät öffnen." In Programmierleitfaden IBM ROM BIOS, 88–89. Wiesbaden: Vieweg+Teubner Verlag, 1989. http://dx.doi.org/10.1007/978-3-322-99741-8_97.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Kumar, M. "800 Chemical Shifts and Coupling Constants for C8H16FP." In Chemical Shifts and Coupling Constants for Phosphorus-31, 809. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_802.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Kumar, M. "801 Chemical Shifts and Coupling Constants for C8H16NO2P." In Chemical Shifts and Coupling Constants for Phosphorus-31, 810. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_803.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kumar, M. "802 Chemical Shifts and Coupling Constants for C8H16NO3P." In Chemical Shifts and Coupling Constants for Phosphorus-31, 811. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_804.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Kumar, M. "803 Chemical Shifts and Coupling Constants for C8H16NO3P." In Chemical Shifts and Coupling Constants for Phosphorus-31, 812. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_805.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kumar, M. "805 Chemical Shifts and Coupling Constants for C8H16NO3PS2." In Chemical Shifts and Coupling Constants for Phosphorus-31, 814. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_807.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kumar, M. "806 Chemical Shifts and Coupling Constants for C8H16NO3PS3." In Chemical Shifts and Coupling Constants for Phosphorus-31, 815. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_808.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kumar, M. "807 Chemical Shifts and Coupling Constants for C8H16NO4P." In Chemical Shifts and Coupling Constants for Phosphorus-31, 816. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-32069-9_809.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "321.804 3"

1

Goldman, S., J. Copeland, T. Moritz, W. Henderson, and L. A. Harker. "EFFECT OF ANTIPLATELET THERAPY ON EARLY GRAFT PATENCY AFTER CORONARY ARTERY BYPASS GRAFTING: VA COOPERATIVE STUDY # 207." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643612.

Повний текст джерела
Анотація:
To determine if specific antiplatelet therapy improved graft patency after coronary artery bypass grafting (CABG) -we compared (1) aspirin(325 mg qd), (2)aspirin(325 mg tid),(3) aspirin and dipyridamole(325 mg and 75 mg resp.tid), (4) sulfinpyrazone(267 mg tid) and (5) placebo(tid).Therapy was started 48 hours before CABGexcept for aspirin. When aspirin was a treatment,one 325 mg dose was given12 hours before surgery. Graft patency data were obtained early, one week, and then later, one year, after surgery. Preliminarydata, based on local interpretation of the angiograms at each center, in the firs 496 patients (1711 grafts), revealed thefollowing early graft patencies: aspiri qd (93%), aspirin tid (93%), aspirin and dipyridamole (93%),and sulfinpyrazone (92%). All these therapies improved(P<0.005)early graft patency compared to placebo (84%). Chest tube drainage measured within the first 35 hours after CABG revealed that the median loss with aspirintid (1114 ml) and aspirin and dipyridamole (972 ml) exceeded (P<0.001) placebo (802 ml) while aspirinqd (880 ml) and sulfinpyrazone (750 ml) did not. The reoperation rate was greater(P<0.01) in all the treatment groups thatcontained aspirin (6.1%) compared to the two non aspirin groups (1.9%). Overall operative mortality was 2.1%. In conclusion, graft patency was improved early after CABG with antiplatelet therapy. Two regimens which included preoperative aspirin has increased blood loss after CABG and preoperative aspirin increased the reoperation rate.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Daenen, Laura G. M., Jeanine M. L. Roodhart, Julia M. Houthuijzen, Edwin C. A. Stigter, Johan Gerrits, Arjan B. Brenkman, and Emile E. Voest. "Abstract 840: High levels of hexadeca-4,7,10,13-tetraenoic acid (16:4(n-3)) in fish oil induce resistance to chemotherapyin vivo." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-840.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Aktas, Levent, Nam Hoang Vu, and M. Cengiz Altan. "Effect of High Temperature Exposure on the Mechanical Properties and Moisture Absorption Kinetics of Graphite/Epoxy Laminates." In ASME 2006 International Mechanical Engineering Congress and Exposition. ASMEDC, 2006. http://dx.doi.org/10.1115/imece2006-15133.

Повний текст джерела
Анотація:
This study investigates the effect of exposure to elevated temperatures on the mechanical properties and moisture absorption kinetics of a graphite/epoxy composite laminate. 16-ply unidirectional AS4/3501-6 laminates are cured in an autoclave. The temperature profile during cure cycle involves a ramp of 5°C/min followed by a 3-hour hold at 177°C (350°F). The test samples obtained from these laminates are subjected to 150, 200, 250, 275, 300 and 325°C for 30min. Flexural strength and stiffness of the samples are characterized by three-point bending tests before and after the temperature exposure. These samples are then immersed into distilled water at 80°C and weighed at regular intervals to characterize their moisture absorption kinetics. Stiffness remained nearly unaffected from exposure to elevated temperatures except for 300 and 325°C. At 300 and 325°C, up to 21% and 58% reductions in flexural stiffness with respect to the control samples is observed, respectively. On the other hand, flexural strength displayed slight reduction at 250°C and resulted in over 60% and 88% deterioration for 300 and 325°C, respectively. Exposure to 150 and 200°C did not result in significant changes in mechanical properties. However, moisture absorption experiments indicated an increase in the rate of diffusion even if the mechanical properties are unaffected. The diffusion coefficient displayed an increase of 27% for 150°C, 75% for 200°C, reaching a maximum increase of 600% for 300°C exposure.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Zekert, F., A. Hufnagl, A. Hufnagl, and M. A. A. Kratzer. "FIRST EXPERIENCE WITH A NEW SYSTEM TO MEASURE PRIMARY HEMOSTASIS IN VITRO." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643078.

Повний текст джерела
Анотація:
Control of hemostatic parameters of patients undergoing surgery usually involves only determination of parameters of the coagulation cascade, but not measurement of primary hemostasis. This has mainly methodological reasons. Recently a model of primary hemostasis has been introduced (Kratzer & Bom, Haemostasis 15:357; 1985) now produced under the name “ Thrombostat 4000” (VDG von der Goltz, 8221 Seeon, West Germany). This device measures computerized within minutes “ in vitro” bleeding parameters (vBP) like bleeding volume (V,ul), time (T,sec) and the viscosity depending initial flow (IF,ul/min) in a small sample (0.5-lml) of whole anticoagulated blood (Na citrate 1 to 10). The clinical relevance of the vBP was tested in patients undergoing major surgery.Results : Case 1: A 78 years old woman with osteomyelosarcoma, heavy bleeding and normal coagulation parametrs showed strongly pathological vBP: (V > 800, T > 300, IF 184); control values: (V = 177, T = 105, IF = 145); An improvement of beeding and shortening of vBP was observed after infusion of platelet concentrate: (V = 328, T = 245, IF = 147).Case 2: A 60 years old man with adenocarcinoma undergoing liver transplantation, before operation (OP) vBP: (V = 224, T = 114, IF = 182); displayed a strong increase during OP: (V > 800, T = 360, IF = 277; decreasing values after Oft (V = 348, T = 146, IF = 254); 1. day after OP: (V = 250, T = 127, IF = 221); 13 day after OP normal vBft (V = 160, T = 111, IF 182).Case 3: A 35 years old man with III. grade burnings of the skin (35%) and a massive platelet function defect: (V > 800, T > 180, IF = 328); improvement after infusion of platelet concentrate: (V = 393, T = 164, IF = 239); further improvement some hours later: (V = 240, T = 120, IF = 213); and normalizing of parameters at the 1. day: (V = 197, T = 126, IF = 186) and the 5. day after OP: (V = 130, T = 122, IF = 142).It is interesting to note that patients with heavy burnings reguarly displayed reduced vBP: (V = 120, T = 70, IF = 127) if measured very early after the accident. The new method seems to be a valuable instrument to judge platelet functions.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lee, Sangju, Eberhard Bamberg, and Charles Eason. "Rapid Prototyping of Full Scale House Structures." In ASME 2011 International Manufacturing Science and Engineering Conference. ASMEDC, 2011. http://dx.doi.org/10.1115/msec2011-50179.

Повний текст джерела
Анотація:
This paper reports on the machining of a construction material (aerated concrete) with a rapid prototyping device, Shapemaker III, which is based on waterjet technology. Preliminary machining tests were carried out to investigate machining conditions (speed and pressure) of separation cuts. Cutting speeds for the waterjet were investigated for two aerated concrete construction materials; autoclaved aerated concrete (AAC) in two strengths (348 and 580 psi compressive strength) and a non-autoclaved, fiber reinforced aerated concrete (FRAC) with a 450 psi compressive strength. Cutting samples were prepared in four thicknesses (0.5, 1, 2, and 3 inches) and cut at two pressures (40 and 60 ksi). The 0.5 and 1 inch specimens were cut with good surface finish at over 600 in/min at 40 ksi. The 2 and 3 inch specimens could be cut at 320 and 80 in/min at 40 ksi, respectively. The experimental data was used in the fabrication of rapid prototyping houses with a pure waterjet machine. As results, full scale houses were fabricated with FRAC and Styrofoam. Additionally, a sub-mold of an outdoor fireplace was manufactured with Styrofoam for casting of customized aerated concrete blocks.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Jakubowski, J. A., and D. Deykin. "NIACIN-INDUCED PROSTACYCLIN (PGI2) GENERATION AND THE SEARCH FOR THE IDEAL DOSE OF ASPIRIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643370.

Повний текст джерела
Анотація:
We have previously reported that chronic administration of 80 mg/day of enteric-coated aspirin (ECA) in three divided doses of 27 mg each day for 7 days produced over 90% inhibition of platelet thromboxane production. What we wanted to know was whether that dose of aspirin spared PGI2 production. We developed a sensitive plasma assay for PGI2 (measured as 6-keto-PGF1a). We confirmed the reports of others that normal plasma levels are very low, less than 2 pg/ml. We selected niacin as a provocative challenge to raise plasma levels of PGI2 to test the ability of a given aspirin regimen to spare or suppress PGI2 production in vivo. In 5 normal subjects an oral dose of 3 mg/kg of niacin produced a 3-fold rise in 6-keto-PGF1a from 0.86 to 2.64 pg/ml. A dose of 5 mg/kg produced a rise to 6.6 pg/ml. Administration of 323 mg of regular aspirin/day for 7 days completely abolished niacin-induced elevation of plasma PGI2. The lowest dose of ECA that we have found effective in suppressing platelet thromboxane production in vitro, 80 mg/day in divided doses of 27 mg three times a day for 7 days, also completely suppressed niacin-induced elevation of PGI2. Our data do not support the hyypothesis that a very low dose of ECA selectively suppress platelet thromboxane production but spares generation of PGI2
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lee, Heung N., Sang-Hoon Kang, Hong Joo Ahn, Wook Hyun Sohn, and Kwang Yong Jee. "Determination of 35S in Radioisotope Wastes by a Wet Oxidation." In The 11th International Conference on Environmental Remediation and Radioactive Waste Management. ASMEDC, 2007. http://dx.doi.org/10.1115/icem2007-7291.

Повний текст джерела
Анотація:
The oxidation studies of a sulfur to a sulfate ion by various oxyhalide oxidants in organic (thiourea, methionine) and inorganic (sulfate, thiophosphate) compounds were carried out in an acidic solution. The optimized result of the oxidation reaction was obtained when a bromate compound (BrO3−) as an oxidant and a 3 M HNO3 solvent. The chemical yield for the oxidation of the organic and inorganic sulfur compounds to a sulfate ion was monitored as 80% for thiophosphate, 87% for methionine, and 100% for thiourea and sulfate within 5% RSD. The oxidation of thiourea required at least 1.6 equivalents of the bromate in an acidic solution. In the case of the oxidation of methionine and thiophosphate, the oxidation yield was above 80% if the bromate was used at 20 times that of the substrates. The chemical yield in the paper sample (WypAll) exceeded 100% because of its background sulfur contents (910 ppm). The sulfate ion was quantitatively measured by using GPC and/or LSC counting of 35S followed by precipitates of BaSO4. The interfering nuclides (14C, 32P) were removed in an acidic condition. The minimum detectable activity (MDA) of 35S was found to be 0.1 Bq/g.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Raimondi, Lucrezia, Laura Di Benedetto, Paolo Ciracì, Rachele Lazzeroni, Filippo Maria Raimondi, Gian Paolo Spinelli, and Giuseppe Naso. "CIRCULATING TUMOR DNA OF CEREBROSPINAL FLUID SAMPLES IN TRIPLE-NEGATIVE BREAST CANCER: USEFULNESS OF LONGITUDINAL ASSESSMENT FOR EARLY DETECTION OF BRAIN METASTASIS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2008.

Повний текст джерела
Анотація:
Objectives: Triple-negative breast cancer (TNBC) still has poor prognosis for a higher rate of relapse and a greater tendency of developing brain metastasis (BrM) compared with other major breast cancer subtypes. Circulating tumor DNA (ctDNA) represents a valuable tool associated with the outcome and the aggressiveness of breast cancer. Biomarkers allowing to predict the development of BrM in TNBC are needed. We studied the usefulness of assessment of CSF-ctDNA for identification early at-risk patients to develop BrM in TNBC. Methodology: A total of 323 newly diagnosed nonmetastatic TNBC patients who underwent neoadjuvant therapy + surgery (NACT) with complete response (CR) were prospectively enrolled. After surgery, CSF-ctDNA collected from all patients enrolled was extracted and assessed using the QIAamp Circulating Nucleic Acid Kit. Survival curves were estimated by using Kaplan–Meier method and compared with the log-rank test. Multivariate Cox regression was used to identify the risk of mortality at 3 years. Results: After NACT, CSF-ctDNA was detectable in 126/323 (39%) patients, 101/126 (80%) were diagnosed at Stage 3. A total of 124 out of 126 (98.4%) ctDNA+ patients subsequently developed BrM. In contrast, only 2 (2/197, 1%) ctDNA− patients subsequently developed BrM and 195 other patients remain in a CR (p <0.001, Fisher’s exact test). CSF-ctDNA did associate with PFS and OS: undetectable ctDNA was associated with superior PFS (HR 0.3; p=0.002) and OS (HR 0.2; p<0.01), indicating survival is largely determined by the onset of BrM. With a median follow-up of 3 years, median PFS of ctDNA+ versus ctDNA− patients was 13 months versus not reach, p=0.004 (log-rank test). Median OS for ctDNA+ versus ctDNA− patients was 16 months after NACT versus not reach, p=0.0016 (log-rank test). At multivariate analysis, detectable CSF-ctDNA emerged as the best predictor of the development of BrM and 24-month mortality (HR: 3.62; p <0.0001). Age, stage, Ki67%, and response to chemotherapy were not significantly associated with the prognosis. Conclusion: After NACT, detectable CSF-ctDNA significantly associated with PFS and OS, identifying early at-risk patients to develop BrM in TNBC who should take advantage from appropriate additional treatment, remains a critical problem.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Berkner, J. A., G. Mitra, and J. W. Bloom. "MONOCLONAL ANTIBODY BINDING TO FACTOR VIII:C." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644063.

Повний текст джерела
Анотація:
The interactions of monoclonal antibodies with highly purified Factor VIII:c have been studied utilizing the ELISA technique. ELISA plates were coated with Factor VIII:c, protein A purified monoclonal IgG was then added and bound antibody detected with peroxidase labeled antimouse IgG. A Scatchard-Sips plot approach to data analysis was used to calculate binding constants. The binding constants for four antibodies designated BD10, AD7, C7F7 and 39MH8 were as follows: BD10, KO = 7.1 x 108 M-1, n = 1.1 (moles antibody/moles ligand); AD7, KO = 3.1 x 108 M-1, n = 2.7; C7F7, KO = 3.6 x 1011M-1, n = 0.03; 39MH8, K = 6.0 x 1011 M-1, n = 0.03. The binding constants for C7F7 to the purified carboxy-terminal (residues 1649-2332) 80 kD functional region of the Factor VIII:c molecule were also determined: KO = 1.0 x 1011 M-1, n = 0.55. On the basis of these results the following conclusions can be drawn: 1) the antibodies can be divided into two groups: high affinity (suitable for use in immunopurification), C7F7 and 39MH8; low affinity: BD10 and AD7; 2) the antibodies in the low affinity group have valance values two orders of magnitude higher than the high affinity antibodies, C7F7 and 39MH8. The difference might be explained by the high affinity antibody epitopes on the immobilized Factor VIII:c being less exposed to the solution; 3) C7F7 binding to the 80 kD polypeptide, compared to the whole Factor VIII:c molecule, gave virtually identical Kc values, but dramatically different valance values. This suggests that the C7F7 epitope is more accessible on the 80 kD polypeptide.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Трейстер, М. Ю., та М. Прюх. "ПОГРЕБЕНИЕ СРЕДНЕСАРМАТСКОГО ВРЕМЕНИ В ОКРЕСТНОСТЯХ ТАНАИСА С КИТАЙСКОЙ ЛАКОВОЙ ЧАШЕЙ «ЭР БЭЙ»". У SCYTHIA et SARMATIA : Сборник статей. Crossref, 2020. http://dx.doi.org/10.25681/iaras.2019.978-5-317-06274-3/328-337.

Повний текст джерела
Анотація:
В 1987 г. экспедицией Ростовского университета в кургане 46 могильника Царский , в окрестностях Танаиса, было открыто погребение женщины с ребёнком последней трети I первой половины II в. н.э. Среди находок в заполнении могильной ямы Л.С. Ильюков отметил лоскутки красной и чёрной краски с поверхности истлевшего ларца . Эти фрагменты были атрибутированы одним из авторов во время работы в фондах Музея-Заповедника Танаис в 2015 г. как остатки лака китайского изделия. Декор фрагментов (в частности мотив двойного феникса ) позволяет определить их как части чаши с боковыми выступами-ручками erbei ханьского времени. Такие чаши производили как в государственных, так и в частных мануфактурах, чаще в виде наборов. Качество росписи сохранившихся фрагментов свидетельствует о том, что чаша из могильника Царский была изготовлена в одной из государственных мастерских Шу и Гуанхань в совр. провинции Сычуань. Такие чаши изготавливались начиная со среднего периода династии Западной Хань, т.е. ок. 150 г. до н.э., и продолжали оставаться в репертуаре лакового производства и в период династии Восточной Хань, примерно до 80 г. н.э.
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "321.804 3"

1

Becher, Julie, Samuel Beal, Susan Taylor, Katerina Dontsova, and Dean Wilcox. Photo-transformation of aqueous nitroguanidine and 3-nitro-1,2,4-triazol-5-one : emerging munitions compounds. Engineer Research and Development Center (U.S.), August 2021. http://dx.doi.org/10.21079/11681/41743.

Повний текст джерела
Анотація:
Two major components of insensitive munition formulations, nitroguanidine (NQ) and 3-nitro-1,2,4-triazol-5-one (NTO), are highly water soluble and therefore likely to photo-transform while in solution in the environment. The ecotoxicities of NQ and NTO solutions are known to increase with UV exposure, but a detailed accounting of aqueous degradation rates, products, and pathways under different exposure wavelengths is currently lacking. We irradiated aqueous solutions of NQ and NTO over a 32-h period at three ultraviolet wavelengths and analyzed their degradation rates and transformation products. NQ was completely degraded by 30 min at 254 nm and by 4 h at 300 nm, but it was only 10% degraded after 32 h at 350 nm. Mass recoveries of NQ and its transformation products were >80% for all three wavelengths. NTO degradation was greatest at 300 nm with 3% remaining after 32 h, followed by 254 nm (7% remaining) and 350 nm (20% remaining). Mass recoveries of NTO and its transformation products were high for the first 8 h but decreased to 22–48% by 32 h. Environmental half-lives of NQ and NTO in pure water were estimated as 4 and 6 days, respectively. We propose photo-degradation pathways for NQ and NTO supported by observed and quantified degradation products and changes in solution pH.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Thomas Austin, Evan, Paul Kang, Chinedu Mmeje, Joseph Mashni, Mark Brenner, Phillip Koo, and John C Chang. Validation of PI-RADS v2 Scores at Various Non-University Radiology Practices. Science Repository, December 2021. http://dx.doi.org/10.31487/j.aco.2021.02.02.

Повний текст джерела
Анотація:
Purpose: The purpose of this study was to validate the second version of the Prostate Imaging Reporting and Data System (PI-RADSv2) scores in predicting positive in-bore MRI-guided targeted prostate biopsy results across different non-university related institutions. The study focuses on PI-RADS v2 scoring because during the study period, PI-RADS v2.1 had not been released. Materials and Methods: This was a retrospective review of 147 patients who underwent multiparametric magnetic resonance imaging (mpMRI) of the pelvis followed by in-bore MRI-guided targeted prostate biopsy from December 2014 to May 2018. All lesions on mpMRI were rated according to PI-RADS v2 criteria. PI-RADS v2 scores were then compared to MR-guided biopsy results and pre-biopsy PSA values. Results: Prostate Cancer (PCa) was detected in 54% (80/147) of patients, with more prostate cancer being detected with each subsequent increase in PI-RADS scores. Specifically, biopsy results in patients with PI-RADS 3, 4, and 5 lesions resulted in PCa in 25.6% (10/39), 58.1% (33/55), and 86.0% (37/43) respectively. Clinically significant PCa (Gleason score ≥7) was detected in 17.9% (7/39), 52.7% (29/55), and 72% (31/43) of cases for PI-RADS 3, 4, and 5 lesions respectively. When the PI-RADS scoring and biopsy results were compared across different institutions, there was no difference in the PI-RADS scoring of lesions or in the positive biopsy rates of the lesions. The sensitivity, specificity, PPV, and NPV for PI-RADS 3-4 lesions were also not statistically different across the institutions for detecting Gleason 7 or greater lesions. Conclusion: Our results agree with prior studies that higher PI-RADS scores are associated with the presence of clinically significant PCa and suggest prostate lesions with PI-RADS scores 3-5 have sufficient evidence to warrant targeted biopsy. The comparison of PI-RADS score across different types of non-university practices revealed no difference in scoring and biopsy outcome, suggesting that PI-RADS v2 can be easily applied outside of the university medical center setting. Clinical Relevance: PI-RADS v2 can be applied homogeneously in the non-university setting without significant difference in outcome.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Garcés i Estalló, Ignasi. Sancho Rocher, Laura (2021). El nacimiento de la democracia. El experimento político ateniense (508-322 a. C.). Ático de los Libros. Barcelona. 335 págs., figuras en b/n en el texto. ISBN: 978-84-18217-33-3. Edicions i Publicacions de la Universitat de Lleida, 2021. http://dx.doi.org/10.21001/rap.2020.20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Brown, Yolanda, Twonia Goyer, and Maragaret Harvey. Heart Failure 30-Day Readmission Frequency, Rates, and HF Classification. University of Tennessee Health Science Center, December 2020. http://dx.doi.org/10.21007/con.dnp.2020.0002.

Повний текст джерела
Анотація:
30 Day Hospital Readmission Rates, Frequencies, and Heart Failure Classification for Patients with Heart Failure Background Congestive heart failure (CHF) is the leading cause of mortality, morbidity, and disability worldwide among patients. Both the incidence and the prevalence of heart failure are age dependent and are relatively common in individuals 40 years of age and older. CHF is one of the leading causes of inpatient hospitalization readmission in the United States, with readmission rates remaining above the 20% goal within 30 days. The Center for Medicare and Medicaid Services imposes a 3% reimbursement penalty for excessive readmissions including those who are readmitted within 30 days from prior hospitalization for heart failure. Hospitals risk losing millions of dollars due to poor performance. A reduction in CHF readmission rates not only improves healthcare system expenditures, but also patients’ mortality, morbidity, and quality of life. Purpose The purpose of this DNP project is to determine the 30-day hospital readmission rates, frequencies, and heart failure classification for patients with heart failure. Specific aims include comparing computed annual re-admission rates with national average, determine the number of multiple 30-day re-admissions, provide descriptive data for demographic variables, and correlate age and heart failure classification with the number of multiple re-admissions. Methods A retrospective chart review was used to collect hospital admission and study data. The setting occurred in an urban hospital in Memphis, TN. The study was reviewed by the UTHSC Internal Review Board and deemed exempt. The electronic medical records were queried from July 1, 2019 through December 31, 2019 for heart failure ICD-10 codes beginning with the prefix 150 and a report was generated. Data was cleaned such that each patient admitted had only one heart failure ICD-10 code. The total number of heart failure admissions was computed and compared to national average. Using age ranges 40-80, the number of patients re-admitted withing 30 days was computed and descriptive and inferential statistics were computed using Microsoft Excel and R. Results A total of 3524 patients were admitted for heart failure within the six-month time frame. Of those, 297 were re-admitted within 30 days for heart failure exacerbation (8.39%). An annual estimate was computed (16.86%), well below the national average (21%). Of those re-admitted within 30 days, 50 were re-admitted on multiple occasions sequentially, ranging from 2-8 re-admissions. The median age was 60 and 60% male. Due to the skewed distribution (most re-admitted twice), nonparametric statistics were used for correlation. While graphic display of charts suggested a trend for most multiple re-admissions due to diastolic dysfunction and least number due to systolic heart failure, there was no statistically significant correlation between age and number or multiple re-admissions (Spearman rank, p = 0.6208) or number of multiple re-admissions and heart failure classification (Kruskal Wallis, p =0.2553).
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "321.804 3" для конкретних типів джерел:
Статті в журналах Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії